CymaBay Therapeutics Company Profile (NASDAQ:CBAY)

CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY."

CymaBay Therapeutics Inc. (NASDAQ:CBAY) released its quarterly earnings data on Thursday, August, 10th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by $0.06. View CymaBay Therapeutics' Earnings History.

CymaBay Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for CymaBay Therapeutics.

9 equities research analysts have issued 1-year price objectives for CymaBay Therapeutics' shares. Their forecasts range from $12.00 to $16.00. On average, they expect CymaBay Therapeutics' stock price to reach $14.00 in the next year. View Analyst Ratings for CymaBay Therapeutics.

Here are some recent quotes from research analysts about CymaBay Therapeutics stock:

• 1. Cantor Fitzgerald analysts commented, "Interim Phase 2 data as good as it gets. Seladelpar’s efficacy in PBC was established in a Phase 2 trial that tested 50mg or 200mg daily doses. Problematic were safety signals that led to termination of the study." (9/19/2017)
• 2. According to Zacks Investment Research, "CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based in Newark, California. " (9/18/2017)
• 3. HC Wainwright analysts commented, " Recall, on December 7, CymaBay initiated an open-label, dose-ranging Phase 2 study (NCT02955602) of seladelpar (MBX-8025) in about 36 patients with primary biliary cholangitis (PBC) who are not adequately responding to, or are intolerant of, ursodeoxycholic acid (UCDA). Notably, the study sites are located in U.S., Canada, Germany and the U.K. Per protocol, patients are randomized to either 5 mg or 10 mg for 8 weeks. Based on review of the safety and efficacy of the 8 week data, new patients are then enrolled to receive 25 mg of seladelpar for 8 weeks. We also point out that the study incorporates an extension phase where patients are able to continue treatment for a total of 26 weeks, thus allowing for dose adjustments. In this trial, the primary endpoint is the reduction of alkaline phosphate (ALP) from baseline. Preliminary results from the first two cohorts (5 mg and 10 mg) are expected in early 3Q17 (likely July), with data readout of the third cohort (25 mg) anticipated by year end. Ahead of this important, near-term value inflection, we affirm our Buy rating on CBAY shares and raise our price target to $7." (3/27/2017)
• 4. Piper Jaffray Companies analysts commented, "CymaBay ended 2016 with cash of $17 million, and subsequently CymaBay received $5 million upfront from Kowa in January and raised net proceeds of $9.2 million in February bringing pro forma cash to ~$31 million. CymaBay will report Phase II data on 5mg and 10mg seladelpar in primary biliary cholangitis (PBC) in 3Q:17 followed by 25mg seladelpar data in 4Q:17. We will look for ALP reduction with enhanced liver safety following 3 transaminase elevations at higher doses in the prior study. Encouraging preclinical data for seladelpar in NASH could lead to a pre-IND meeting with the FDA in 2Q:17. CymaBay has partnered Phase III-ready arhalophenate with Kowa in the U.S., and could partner in Europe. We reiterate our Overweight rating and are increasing our price target to $6.50 from $5 by adding value for seladelpar in NASH." (3/24/2017)

CymaBay Therapeutics saw a increase in short interest during the month of September. As of September 29th, there was short interest totalling 1,489,737 shares, an increase of 35.1% from the September 15th total of 1,102,943 shares. Based on an average daily volume of 838,810 shares, the short-interest ratio is presently 1.8 days. Approximately 3.7% of the company's stock are short sold.

Some companies that are related to CymaBay Therapeutics include Coherus BioSciences (CHRS), Aclaris Therapeutics (ACRS), Audentes Therapeutics (BOLD), Dova Pharmaceuticals (DOVA), Aduro Biotech (ADRO), Adaptimmune Therapeutics PLC (ADAP), MacroGenics (MGNX), Paratek Pharmaceuticals (PRTK), Synergy Pharmaceuticals (SGYP), G1 THERAPEUTICS (GTHX), Axovant Sciences Ltd (AXON), Calithera Biosciences (CALA), Achaogen (AKAO), Madrigal Pharmaceuticals (MDGL), Rigel Pharmaceuticals (RIGL), Achillion Pharmaceuticals (ACHN), Insys Therapeutics (INSY) and Karyopharm Therapeutics (KPTI).

CymaBay Therapeutics' management team includes the folowing people:

• Robert James Wills Ph.D., Chairman of the Board
• Sujal Shah, Interim President, Interim Chief Executive Officer, Chief Financial Officer
• Charles A. McWherter Ph.D, Senior Vice President, Chief Scientific Officer
• Daniel Menold, Vice President - Finance, Principal Financial Officer, Principal Accounting Officer
• Kirk Rosemark, Vice President - Regulatory Affairs and Quality Assurance
• Pol F. Boudes M.D., Chief Medical Officer
• Robert Booth Ph.D., Director
• Caroline Loewy, Director
• Evan A. Stein M.D. Ph.D., Director
• Paul F. Truex, Director

Shares of CymaBay Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CymaBay Therapeutics stock can currently be purchased for approximately $8.14.